Supplementary materials: Estimating the risk of thrombotic events in people with congenital hemophilia A using US claims data

<b>These are peer-reviewed supplementary tables for the article '</b><b>Estimating the risk of thrombotic events in people with congenital hemophilia A using US claims data</b><b>' published in the </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Supplemental Table 1A. </b>ICD-9-CM and ICD-10-CM codes used to identify myocardial infarctio<b>n.</b><b>Supplemental Table 1B. </b>ICD-9-CM and ICD-10-CM codes used to identify pulmonary embolism.<b>Supplemental Table 1C. </b>ICD-9-CM and ICD-10-CM codes used to identify ischemic stroke.<b>Supplemental Table 1D. </b>ICD-9-CM and ICD-10-CM codes used to identify deep vein thrombosis.<b>Supplemental Table 1E. </b>ICD-9-CM and ICD-10-CM codes used to identify device-related thrombosis.<b>Supplemental Table 2A. </b>ICD-9-CM and ICD-10-CM codes to identify HIV.<b>Supplemental Tabl</b><b>e 2B</b><b>.</b> ICD-9-CM and ICD-10-CM codes to identify hepatitis C.<b>Supplemental Table 3. </b>Adjusted IRR (95% CI) by age group.<b>Summary: </b><b>Aim:</b> Compare thrombotic risk in people with congenital hemophilia A (PwcHA) to the general non-hemophilia A (HA) population. <b>Patients &amp; methods:</b> US claims databases were analyzed to identify PwcHA. Incidence rates of myocardial infarction, pulmonary embolism, ischemic stroke, deep vein thrombosis and device-related thrombosis were compared with a matched cohort without HA. <b>Results:</b> Over 3490 PwcHA were identified and 16,380 individuals matched. PwcHA had a similar incidence of myocardial infarction and pulmonary embolism compared with the non-HA population, but a slightly higher incidence of ischemic stroke and deep vein thrombosis. The incidence of device-related thrombosis was significantly higher in PwcHA. <b>Conclusion:</b> This analysis suggests that PwcHA are not protected against thrombosis, and provides context to evaluate thrombotic risk of HA treatments.